Patent 7727527 was granted and assigned to Genentech on June, 2010 by the United States Patent and Trademark Office.
The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.